This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Epizyme, Inc. (EPZM) reported a loss of 56 cents per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of loss of 63 cents but wider than the year-ago loss of 41 cents.
Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Agenus Inc. (AGEN) reported first-quarter 2017 loss of 18 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 32 cents and the year-ago loss of 37 cents.
Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View
by Zacks Equity Research
GlaxoSmithKline plc's (GSK) first quarter results came roughly in line with expectations. Glaxo reported first-quarter 2017 core earnings of 62 cents per American Depositary Share (ADS), in line with the Zacks Consensus Estimate.
Glaxo (GSK) Beats Earnings and Revenues in Q1
by Zacks Equity Research
Glaxo reported core earnings of 63 cents per American depositary share, which marginally beat our consensus estimate of 62 cents.
Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More
by Zacks Equity Research
Here we have four pharma companies that are set to report first-quarter results on Apr 26. Let's see how things are shaping up for this quarter.
What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?
by Zacks Equity Research
GlaxoSmithKline plc (GSK) is scheduled to report first-quarter 2017 results on Apr 26 before market opens. Last quarter, the company delivered a positive earnings surprise of 14.04%.
Why Juno Therapeutics' Stock Tumbled in the Past One Year
by Zacks Equity Research
Juno Therapeutics, Inc.'s (JUNO) stock has significantly underperformed Zacks classified Medical-Biomed/Genetics industry in the past one year.
Mylan Down on FDA Warning Letter to Manufacturing Facility
by Zacks Equity Research
Shares of Mylan, Inc. (MYL) dropped 2% after the company received a warning letter from the FDA for its manufacturing facility in India
Inovio's Ebola Vaccine Positive in Expanded Phase I Study
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) recently reported positive preliminary results from the expanded stage of its phase I study, EBOV-001.
Novartis (NVS) In-Licenses Ophthalmic Drug from Lubris LLC
by Zacks Equity Research
Novartis AG (NVS) recently announced that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide from Lubris LLC.
Novartis' Tafinlar, Mekinist Get EU Approval for NSCLC
by Zacks Equity Research
Novartis AG (NVS) recently announced that the European Commission has approved Tafinlar in combination with Mekinist for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC).
GlaxoSmithKline Initiates Phase III Study with Mepolizumab
by Zacks Equity Research
GlaxoSmithKline plc (GSK) announced the initiation of a phase III study with Nucala (mepolizumab,) in patients with severe hypereosinophilic syndrome (HES).
Mylan Receives CRL for Generic Advair Diskus From the FDA
by Zacks Equity Research
Mylan N.V. (MYL) recently suffered a huge setback when it received a complete response letter from the FDA regarding its ANDA for the generic version of asthma drug Advair Diskus.
J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe
by Zacks Equity Research
Johnson & Johnson (JNJ) announced that the French health authority has granted approval to expand the label of Eprex to include treatment of symptomatic anaemia in patients with low or intermediate risk myelodysplastic syndromes (MDS).
Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma
by Zacks Equity Research
Merck & Co., Inc. (MRK) recently announced that its anti-PD-1 therapy, Keytruda, has received positive opinion from CHMP for the treatment of patients with relapsed or refractory classical hodgkin lymphoma (cHL).
Novartis' Acute Heart Failure Drug Fails in Late-Stage Study
by Zacks Equity Research
Novartis AG (NVS) recently suffered a setback on the announcement of disappointing data from a phase III study, RELAX-AHF-2, on pipeline candidate serelaxin (RLX030).
Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod
by Zacks Equity Research
Allergan plc (AGN) announced yesterday that the FDA has approved its Juvederm Vollure XC dermal filler for correction of facial wrinkles and folds in adults over the age of 21.
6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
by Zacks Equity Research
Glaxo carries a Zacks Rank #2 (Buy).
Novartis (NVS) Announces Positive Data on Heart Failure Drug
by Zacks Equity Research
Novartis AG (NVS) recently announced results of a new post-hoc analysis from the PARADIGM-HF study on heart failure drug Entresto.
AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal
by Zacks Equity Research
London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for investigational drug ZS-9.
Why Biotech Stock Gilead (GILD) Could Be a Value Trap
by Arpita Dutt
Gilead's (GILD) valuation looks compelling but is the company really poised for
Glaxo Files for Label Expansion of Influenza Vaccine in US
by Kinjel Shah
GlaxoSmithKline plc (GSK) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA seeking approval to expand the label of Fluarix Quadrivalent ??? an influenza vaccine - for infants six months or older.
Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication
by Zacks Equity Research
Merck & Co., Inc (MRK) announced that it has received FDA approval for Keytruda for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or who had relapsed after three or more prior lines of therapy.
The Zacks Analyst Blog Highlights: Intel, Glaxo, Schwab, Travelers and American Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intel, Glaxo, Schwab, Travelers and American Airlines
Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy
by Zacks Equity Research
Novartis AG (NVS) announced that the FDA has approved Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, HR+/HER2- advanced or metastatic breast cancer.